v3.25.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within the Consolidated Balance Sheets
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets that together reflect the same amounts shown in the unaudited condensed consolidated statements of cash flows (in thousands):
As of March 31,
 20252024
Cash and cash equivalents$211,822 $302,843 
Restricted cash425 — 
Total cash, cash equivalents, and restricted cash$212,247 $302,843 
Schedule of Disaggregation of Total Product Sales
The following table represents total revenues and disaggregates Product sales, net by approved medicine (in thousands):
 Three Months Ended March 31,
 20252024
Product sales, net:  
Livmarli$73,224 $42,845 
Bile Acid Medicines38,361 26,072 
Total product sales, net111,585 68,917 
License and other revenue— 305 
Total revenues$111,585 $69,222 
Schedule of Product Sales by Geographic Area
The following table sets forth Product sales, net by geographic area based on the ship-to location (in thousands):
 Three Months Ended March 31,
 20252024
United States$86,922 $56,111 
Rest of the world24,663 12,806 
Total product sales, net$111,585 $68,917 
Summary of Outstanding Potentially Dilutive Shares of Common Stock Excluded from Calculation of Diluted Net Loss per Share
The following outstanding potential dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:
 As of March 31,
 20252024
Options to purchase common stock and restricted stock units12,712,90812,525,389
Common stock issuable upon conversion of convertible notes9,964,0589,964,247
Employee stock purchase plan contingently issuable51,46548,297
Total22,728,43122,537,933